Annual report [Section 13 and 15(d), not S-K Item 405]

Commitments and Contingencies (Details Narrative)

Commitments and Contingencies (Details Narrative) - USD ($)											1 Months Ended		12 Months Ended
	Sep. 02, 2025	Jul. 09, 2025	Jul. 08, 2025	Jun. 18, 2025	Feb. 17, 2025	Nov. 18, 2024	May 20, 2024	May 13, 2024	Mar. 26, 2021	Jul. 18, 2016	Jun. 30, 2025	May 31, 2025	Dec. 31, 2025	Dec. 31, 2024	Nov. 20, 2025	Feb. 26, 2025	Nov. 21, 2024	Apr. 25, 2024	Aug. 24, 2022
Loss Contingencies [Line Items]
Issuance of pre-funded warrants												24,390
Exercise price												$ 2.46				$ 2.8375
Change in fair value of warrant liability													$ (241,000)	$ (800,000)
Issuance of common stock in settlement of vendor payable														810,000
Issuance of common stock and warrants for services											$ 718,000	$ 718,000	718,000
Research and development expense													$ 3,472,000	$ 5,798,000
Contigency minimum required																	$ 2,500,000
Common stock, par value													$ 0.001	$ 0.001	$ 0.001
Minimum bid price requirement description													had closed below $1 per share for 30 consecutive business days and, as a result, the Company was not in compliance with the $1 minimum bid price requirement for continued listing on the Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”).
Share price															$ 1.00
2023 Sponsored Research Agreement [Member]
Loss Contingencies [Line Items]
Aggregate research and development expense				$ 1,900,000			$ 1,700,000
Payments of research and development				$ 216,000
Research and development expense													$ 863,000	$ 1,078,000
2016 Exclusive Patent License Agreement [Member]
Loss Contingencies [Line Items]
Research and development expense													50,000	145,000
Proceeds from upfront amount								$ 145,000		$ 200,000
License maintenance fees								$ 100,000		100,000
Royalty fee percentage								6.00%
Performance milestone payments								$ 3,100,000		3,100,000
One-time sales milestone payments								1,000,000		1,000,000
Gross sales								250,000,000		250,000,000
Sales revenue								5,000,000		5,000,000
Cumulative gross sales								500,000,000		$ 500,000,000
Royalty expense year one								250,000
Royalty expense years two through five								2,000,000
Royalty expense year six and thereafter								$ 5,000,000
2016 Exclusive Patent License Agreement [Member] \| Minimum [Member]
Loss Contingencies [Line Items]
Royalty fee percentage								1.00%		4.00%
2016 Exclusive Patent License Agreement [Member] \| Maximum [Member]
Loss Contingencies [Line Items]
Royalty fee percentage								5.00%		6.00%
2016 Exclusive Patent License Agreement [Member] \| 2017 through 2020 [Member]
Loss Contingencies [Line Items]
License maintenance fees										$ 200,000
2016 Exclusive Patent License Agreement [Member] \| Beginning in 2022 [Member]
Loss Contingencies [Line Items]
Annual royalty payments										250,000
2016 Exclusive Patent License Agreement [Member] \| Beginning in 2025 [Member]
Loss Contingencies [Line Items]
License maintenance fees								$ 50,000
Annual royalty payments										2,000,000
2016 Exclusive Patent License Agreement [Member] \| Beginning in 2027 [Member]
Loss Contingencies [Line Items]
Annual royalty payments										$ 5,000,000
2021 Exclusive License Agreement [Member]
Loss Contingencies [Line Items]
Research and development expense													5,000	0
License maintenance fees									$ 5,000
Performance milestone payments									3,100,000
One-time sales milestone payments									1,000,000
Gross sales									250,000,000
Sales revenue									5,000,000
Cumulative gross sales									500,000,000
Upfront license fee									20,000
Royalty expense year one though four									250,000
Royalty expense year five and thereafter									$ 2,000,000
2021 Exclusive License Agreement [Member] \| Minimum [Member]
Loss Contingencies [Line Items]
Royalty fee percentage									2.50%
2021 Exclusive License Agreement [Member] \| Maximum [Member]
Loss Contingencies [Line Items]
Royalty fee percentage									5.00%
2024 GTB-3650 Clinical Trial Agreement [Member]
Loss Contingencies [Line Items]
Research and development expense													750,000	190,000
Annual royalty payments						$ 2,000,000
Unbilled and unaccrued amounts													1,100,000
Cytovance Biologics Inc [Member]
Loss Contingencies [Line Items]
Research and development expenses													743,000	2,335,000
Cash payments													$ 1,054,000	$ 3,857,000
Issuance of pre-funded warrants													326,251
Exercise price													$ 0.0001
Change in fair value of warrant liability													$ 847,000
Issuance of common stock in settlement of vendor payable, shares														127,597
Issuance of common stock in settlement of vendor payable														$ 810,000
Issuance of common stock and warrants for services													169,000
Cytovance Biologics Inc [Member] \| Research and Development Expense [Member]
Loss Contingencies [Line Items]
Research and development expenses													$ 743,000	$ 2,335,000
Cytovance Biologics Inc [Member]
Loss Contingencies [Line Items]
Equity method investment, ownership percentage																		9.90%	4.90%
Z One LLC [Member]
Loss Contingencies [Line Items]
Principal amount					$ 150,000
Damages sought value					$ 500,000
Coby Silberfein [Member]
Loss Contingencies [Line Items]
Principal amount	$ 150,000	$ 100,000	$ 100,000
Damages sought value	$ 100,000
Owes damages excess value	500,000